The International Registry of Acute Coronary Syndromes registry study (ISACS) is both a retrospective and prospective study which was designed in order to obtain data of patients with acute coronary syndromes, and herewith control and optimize internationally guideline-recommended therapies in these countries
Aims of this survey study are (1) documentation of the characteristics of all patients presenting to the ISACS centers with STEMI or NSTEMI (2) documentation of in-hospital outcome, and outcome rates at 6 month and 1 year, (3) documentation of invasive procedures and procedure-associated complications (4) documentation of therapeutic regimens and investigation conformity of treatment with already established guidelines. Investigators: ISACS Administrative Committee: Raffaele Bugiardini (Italy-Principal Investigator) Lina Badimon (Spain) Olivia Manfrini (Italy- Project Coordinator) Edina Cenko (Italy-Center Coordinator) Steering Committee: Mirza Dilic (Bosnia and Herzegovina), Asen Goudev (Bulgaria), Davor Milicic (Croatia), Raffaele Bugiardini, Edina Cenko and Olivia Manfrini (Italy) Gani Bajraktari (Kosovo), Andrejs Erglis and Ilja Zakke (Latvia), Remigius Zaliunas and Olivija Gustiene (Lithuania), Sasko Kedev and Marija Vavlukis (North Macedonia), Mihail Popovici (Moldova), Maria Dorobantu (Romania), Zorana Vasiljevic (Serbia), Eva Goncalvesova and Martin Studenkan (Slovakia) , Alexander N. Parkhomenko (Ukraine) , Christopher P Gale (United Kingdom).
Study Type
OBSERVATIONAL
Enrollment
36,000
University of Bologna
Bologna, Emilia-Romagna, Italy
RECRUITINGAll causes mortality
All causes mortality
Time frame: 30 days, 6 months, 1 year
Cardiovascular mortality
Cardiovascular mortality
Time frame: 30 days, 6 months, 1 year
Recurrent myocardial infarction
Recurrent myocardial infarction
Time frame: 30 days, 6 months, 1year
Pharmacogenetic and cardiovascular genetic studies associated to clinical outcomes
Pharmacogenetic and cardiovascular genetic studies associated to clinical outcomes
Time frame: 6 month, 1 year
Adherence to internationally guideline recommended therapies across the participating countries
Adherence to internationally guideline recommended therapies across the participating
Time frame: discharge, 6 months, 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.